Skip to content

13F-HR filed by Caligan Partners LP

Caligan Partners LP filed this 13F-HR for the quarter ended 2024-06-30, filed 2024-08-14, with 13 holding rows worth $427,996,461.

Accession
0001814554-24-000010
Filed
2024-08-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2024

A holdings report, 13 entries on the cover page, a total value of $427,996,461 stated on the cover page (in dollars after the unit check, H1), rows summing to $427,996,461 with VALUE read as dollars as filed, 13F file number 028-23096. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
LIQUIDIA CORPORATION COM NEW53635D202Stock10,360,945$124,331,340dollars as filed
ALIMERA SCIENCES INC016259202COM16,835,154$93,603,456dollars as filed
ANIKA THERAPEUTICS INC035255108COM1,435,993$36,373,703dollars as filed
EXELIXIS INC COM30161Q104Stock1,525,730$34,283,153dollars as filed
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock4,598,737$28,420,195dollars as filed
VERONA PHARMA PLC925050106SPONSORED ADS1,843,756$26,660,712dollars as filed
EVOLUS INC30052C107COM2,167,790$23,520,522dollars as filed
AGIOS PHARMACEUTICALS INC00847X104COM514,711$22,194,338dollars as filed
ENANTA PHARMACEUTICALS INC29251M106COM1,042,889$13,526,270dollars as filed
MINERALYS THERAPEUTICS INC603170101COM745,758$8,725,369dollars as filed
Y-mAbs Therapeutics Inc984241109Common Stock582,078$7,031,502dollars as filed
NOVABRIDGE BIOSCIENCES44975P103CMN3,374,791$5,635,901dollars as filed
OUTLOOK THERAPEUTICS INC69012T305COM500,000$3,690,000dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001814554-24-000010this filing2024-08-14acceptance time not in the bulk data set